Abstract:4024 Background: Human epidermal growth receptor 2 (HER2) is considered as an oncogenic driver gene in gastric cancer (GC). Immunotherapy has been proven to be effective in GC patients. Previous studies indicated that patients harboring driver mutations were considered as poor candidate for immunotherapy. But the efficacy of immunotherapy for HER2 positive GC has not been defined. We therefore analyzed the immunogenicity of HER2 alterations in GC. Methods: Genomic profiling of DNA from 448 GC was performed using next-generation sequencing on 381 cancer associated genes. The expression of PD-L1 protein was evaluated in 192 GC with the use of an automated immunohistochemical assay (Ventana, SP263). Whole-exome sequencing, copy number variations, RNA-seq and clinical data of 443 GC from The Cancer Genome Altas (TCGA) were also analyzed to further evaluate the immunogenicity of HER2 alterations. TMB was defined as number of somatic non-synonymous mutations in coding regions. HER2 amplification in TCGA was defined as “2” derived from the copy-number analysis algorithms GISTIC. Results: HER2 alterations including amplification, missense and fusion were present in 19.2% (85/443) of TCGA cohort and 11.4% (51/448) of clinical cohort. 14.0% (62/443) of TCGA cohort and 6.0% (27/448) of clinical cohort harbored HER2 amplification. Higher TMB was observed in MSS/MSI-L patients carrying any HER2 alterations in TCGA cohort (P = 0.009). On the contrary, HER2 alterations did not show a higher neoantigen level and HER2 alterations were associated with decreased immunogenicity in terms of immune-related gene mRNA expression and immune infiltrates. In clinical cohort, HER2 alterations was also significantly associated with higher TMB (P = 0.001). Meanwhile, a trend of shrinking proportion of PD-L1 expression was observed in HER2 alteration subgroup (2/23, 8.7%) than HER2 wild-type subgroup (47/169, 27.8%, P = 0.071). Furthermore, HER2 amplification had significant positive associations with HRD score (P = 0.0169) in TCGA cohort which indicated an increased degree of genome instability. Conclusions: Although HER2 alterations in GC were associated with increased TMB, HER2 alterations exhibited poor immunogenicity. These findings indicated that HER2 alterations might confer resistance to immune monotherapy.

PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients

Abstract 1179: A single-cell atlas of human gastric malignancy reveals CD8+ T cell rejuvenation as a mediator of immunotherapeutic response

TP53 Co-Mutational Features and NGS-Calibrated Immunohistochemistry Threshold in Gastric Cancer

Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer.

Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library

Somatic mutations that affect early genetic progression and immune microenvironment in gastric carcinoma

Elevated PD-L1 Expression and Microsatellite Instability in Elderly Patients With Gastric Cancer

Clinical and Genetic Characteristics of Early and Advanced Gastric Cancer

PTCH1 mutation as a potential predictive biomarker for immune checkpoint inhibitors in gastrointestinal cancer

Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer

Occurrence of Low Frequency PIK3CA and AKT2 Mutations in Gastric Cancer.

Development of a Streamlined NGS-based TCGA Classification Scheme for Gastric Cancer and Its Implications for Personalized Therapy

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer

Tumor Mutation Burden And Immunogenicity In Gastric Cancer With Her2 Alterations.

Plasma PIK 3 CA Ctdna Specific Mutation Detected by Next Generation Sequencing is Associated with Clinical Outcome in Advanced Breast Cancer

TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer

Bioinformatics-based analysis of programmed cell death pathway and key prognostic genes in gastric cancer: Implications for the development of therapeutics

Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing

Genomic Alterations in Advanced Gastric Cancer Endoscopic Biopsy Samples Using Targeted Next-Generation Sequencing

Construction and validation of a TP53-associated immune prognostic model for gastric cancer

A comparison analysis of the somatic mutations in early-onset gastric cancer and traditional gastric cancer